Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(10 sites)
United States
University of Alabama at Birmingham Hospital, Birmingham, Alabama UCSF, San Francisco, California Emory University Hospital, Atlanta, Georgia Mass General Brigham, Boston, Massachusetts Tisch Cancer Institute at Mount Sinai, New York, New York Memorial Sloan-Kettering Cancer Center, New York, New York Atrium Health Levine Cancer Institute, Charlotte, North Carolina Penn Medicine, Philadelphia, Pennsylvania Sarah Cannon Research Institute, Nashville, Tennessee The Medical College of Wisconsin, Milwaukee, Wisconsin